Affera

Affera is a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing cardiac arrhythmia market.

[Affera @AfferaEP]

Medtronic receives CE mark approval for the Affera™ Mapping and Ablation System! Find the latest on Affera technologies and clinical programs by following us at @MDT_EPAblation and @medtroniceu #EPeeps #afferaCEmark #affera

[Medtronic Cardiac Ablation @MDT_EPAblation]

Affera™ mapping and ablation system, which includes the Sphere-9™ all-in-one mapping and therapeutic radiofrequency (RF) and pulsed field (PF) ablation catheter, receives CE Mark approval! https://t.co/tSTODAUD3G

[Rebecca Seidel @SeidelRebecca]

Thrilled the first Affera System case took place at Medical Center Hamburg-Eppendorf. Congrats to @AndreasMetzner7 & team. This is the first of sites to come in the next few weeks. Excited to make a difference for patients with this novel innovation #MedtronicEmployee #EPeeps

[Medtronic Cardiac Ablation @MDT_EPAblation]

Just published! The Affera™ Mapping and Ablation System 12-month outcomes that led to CE Mark were just published in @JACCJournals. Read it now: https://t.co/KE4bWQGfVc

[Affera @AfferaEP]

Keep up with Affera technologies and clinical programs via Medtronic Channels: @MDT_Cardiac and @MDT_StructHeart starting today!

[Felix Yang, MD, FACC, FHRS @FYang_EP]

Thoughts after first cases w Affera: 1) having all in one mapping/ablating globe is super efficient (mapped an LAA AT and two SVC ATs on first case- first burn terminations on all three) 2) mapping definition and annotation algorithm is on the money as evidenced above

[Dinesh Sharma MD MPH FHRS @DineshSharmaEP]

I am fortunate to be a site prinicipal investigator for AFFERA's disruptive pulse-field/radiofrequency atrial fibrillation ablation clinical trial. The cardiac electrophysiology community across the world is looking forward to this trial. I had our cent…https://t.co/s1mII9eowa

[Affera @AfferaEP]

Thank you Drs ⁦@EladAnter⁩, Taigen et al. @ClevelandClinic⁩, ⁦@natale_md⁩ , Burkhardt et al. ⁦@tcainstitute⁩ and ⁦⁦@MoussaMansour10⁩ et al. ⁦@harvardmed⁩ for a busy and exciting week for ⁦@AfferaEP⁩ SPHERE PersAF trial!

[Affera @AfferaEP]

This is an exciting day for the Affera, Inc. team. Looking forward to partnering with @Medtronic to improve therapies for cardiac arrhythmia patients worldwide.

https://t.co/eZrWwyWtWw

[Affera @AfferaEP]

First patient treated in US IDE SPHERE PerAF at @MountSinaiNYC by Drs. @VivekReddyMD @jskoruth @billwhangep and others. Affera also announces $75M series C with Bain Capital Life Sciences.

https://t.co/VqHapxtLZm

[Jacob Koruth @jskoruth]

#EPeeps - SinaiNYC- having fun and hoping to improve efficacy and safety

[CircEP @CirculationEP]

*New Research Article* - Pulsed-Field Ablation in Ventricular Myocardium Using a Focal Catheter @eladanter #AHAJournals #Epeeps https://t.co/lMN9C5NGSx

[Affera @AfferaEP]

Great paper by @EladAnter group at @ClevelandClinic with @AfferaEP Sphere9 #latticetip catheter

[Elad Anter @EladAnter]

Pulse-field ablation in the ventricle: In contrast to biophysics of RFA, lesion repetition of PFA has incremental effect on lesion dimensions, likely via a mechanism of permeability preconditioning. Congrats to @yavin_h https://t.co/PKKBtGZPrI @CirculationEP @ClevelandClinic

[Affera @AfferaEP]

@jskoruth showing PFA through scar with @AfferaEP Sphere9 #latticetip catheter.

[Elad Anter @EladAnter]

The impact of PFA in scar. Beautiful work by @jskoruth

[Jacob Koruth @jskoruth]

Dose dependent reversible electroporation - effect on AV node conduction. Follow up from last years data on egm amplitude - transient AV block after the pulse that reverses in <1-2 minutes

[Affera @AfferaEP]

Affera, Inc. Announces Successful First-In-Human Use Of SpherePVI Circumferential Pulmonary Vein Isolation Device ... https://t.co/dpX4NAO0Ry

[Affera @AfferaEP]

Affera ready to redefine another catheter ablation category. Thank you Drs. Aidietis and Račkauskas at Vilnius University Hospital for hosting us and @EladAnter and @VivekReddyMD for joining us to perform successful FIH procedures last week. Stay tuned…

[Elad Anter @EladAnter]

Another PerAF case with Affera PFA: PVI+PWI+MAL: 1st to last lesion <30min with total procedure time <1Hr including mapping and 20min waiting period (no reconnections). We may soon be ready to re-evaluate ablation strategies to treat different types of AF w/ rapid and durable Tx.

[Elad Anter @EladAnter]

Persistent AF case with Affera: PVI+Mitral Line+PWI+CTI with transpired therapy time of 30 min. Multiple cases, durable lines, consistent results. High-Res mapping and PFA/RFA from the same lattice catheter at a switch of a button. Exciting times to be in EP and Cleveland Clinic

[Affera @AfferaEP]

https://t.co/SEgflqGI59

[Moussa Mansour @MoussaMansour10]

Real-time RF/PF case by Vivek Reddy at #AFSymposium2021